Intravenous inotropic agents in the intensive therapy unit: do they really make a difference?

Part of the management of refractory heart failure is treatment aimed at preventing organ damage due to inadequate oxygen delivery, improving hemodynamics, and maximizing cardiac output while maintaining only mildly elevated ventricular filling pressures The aim of this paper is to review the most u...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2000-03, Vol.2 (1), p.7-11
Main Authors: Opasich, Cristina, Russo, Alessandra, Mingrone, Renato, Zambelli, Mara, Tavazzi, Luigi
Format: Article
Language:English
Subjects:
Adrenergic beta-Agonists - administration & dosage
Adrenergic beta-Agonists - therapeutic use
Cardiotonic Agents - administration & dosage
Cardiotonic Agents - therapeutic use
Critical Care
Dobutamine - administration & dosage
Dobutamine - therapeutic use
Heart failure
Heart Failure - drug therapy
Heart Failure - physiopathology
Humans
Infusions, Intravenous
Intensive Care Units
Intensive therapy
Intravenous inotropics
Phosphodiesterase Inhibitors - administration & dosage
Phosphodiesterase Inhibitors - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Part of the management of refractory heart failure is treatment aimed at preventing organ damage due to inadequate oxygen delivery, improving hemodynamics, and maximizing cardiac output while maintaining only mildly elevated ventricular filling pressures The aim of this paper is to review the most updated indications on intravenous inotropic agents, and to compare their cardiac and peripheral effects. Finally, clinical implications of their use (alone or in combination) are reviewed.
ISSN:1388-9842
1879-0844
DOI:10.1016/S1388-9842(99)00061-6